Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Enoxa vs Lovenox in ACS
NCT04552067Phase 1Completed
- Sponsor
- Université de Monastir
- Start
- Dec 2012
- Primary completion
- Apr 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of enoxaparin in acute coronary syndrome (ACS) (2 arms), sponsored by Université de Monastir. Primary endpoint: Anti-Xa Activity at 4 hours. Started Dec 2012; status: completed.
02
Drugs
enoxaparin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT04552067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04552067.